Research Announcement- Denosumab Clinical Study for Children with OI
Date: December 15, 2016
The Osteogenesis Imperfecta Foundation would like to bring to ASBMR members’ attention a multicenter clinical trial currently sponsored by Amgen to study the safety and efficacy of the investigational drug Denosumab on bone mineral and fracture occurrence in children who have osteogenesis imperfecta (OI). Currently, 34 sites in the United States and multiple other countries are participating in this clinical research study. Children ages 2-17 who have a diagnosis of OI Type I through IV are eligible for this 3-year clinical research study.
Visit their Clinical Trials Website to learn more and view a complete list of study locations. If you have any additional questions, please contact the Amgen Call Center at (866) 572-6436. Their study contacts will be able to tell you more about the clinical research study, review eligibility criteria, and find a site near you.